Skip to main content

FDA Approves Vesicare (solifenacin succinate) for the Treatment of Overactive Bladder

Vesicare (solifenacin succinate) is a muscarinic receptor antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence.

Related articles

VESIcare (solifenacin succinate) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.